Form 4: Akero Therapeutics Senior VP Sells Shares Under Pre-Arranged 10b5-1 Plan
Insider Transaction Report
Akero Therapeutics' Senior VP of Commercial Strategy, Patrick Lamy, sold 2,000 shares of common stock for $52.88 per share on July 1, 2025, as part of a pre-arranged 10b5-1 trading plan.
Summary
- Patrick Lamy, Senior VP of Commercial Strategy at Akero Therapeutics, Inc. (AKRO), reported a sale of common stock.
- The transaction involved the disposition of 2,000 shares of common stock.
- The shares were sold at a price of $52.88 per share.
- The transaction date was July 1, 2025.
- Following this transaction, Patrick Lamy beneficially owns 29,891 shares of Akero Therapeutics common stock directly.
- The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on January 6, 2025.
Sentiment
Score: 5
Explanation: The sentiment is neutral as this is a routine disclosure of a pre-planned insider stock sale under a 10b5-1 plan, which typically does not imply new information about the company's performance or outlook.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This filing is a routine disclosure of an insider stock transaction, common across all publicly traded companies. It does not provide specific insights into broader industry trends or competitive landscape beyond the company's stock activity.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Disclosure | The reported transaction was made pursuant to a Rule 10b5-1 trading plan dated January 6, 2025, which allows insiders to set up pre-scheduled trades to avoid accusations of trading on material non-public information. | 01/06/2025 | This demonstrates adherence to good corporate governance practices by ensuring insider trades are pre-planned and transparent, mitigating concerns about opportunistic trading. |
Stakeholder Impact
- Shareholders: The sale of 2,000 shares by a Senior VP is a minor transaction in the context of a publicly traded company and is unlikely to have a significant direct impact on the share price or shareholder value, especially given it was pre-planned.
Key Dates
| Date | Description |
|---|---|
| 01/06/2025 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 07/01/2025 | Date of the reported transaction (sale of common stock). |
| 07/03/2025 | Date the Form 4 filing was signed. |
Keywords
Akero Therapeutics, AKRO, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Patrick Lamy, Equity Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.